ArticleBiochemical pharmacology2018
BRET-based assay to monitor EGFR transactivation by the AT
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Biochemical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- A high-sensitivity TIE2-GRB2 BRET platform for functional and pharmacologic profiling of pathogenic variants associated with venous malformations.Angiogenesis · 2026Article
- Bombesin Receptor Subtype-3 Regulates Tumor Growth by HER2 Tyrosine Phosphorylation in a Reactive Oxygen Species-Dependent Manner in Lung Cancer Cells.Targets (Basel) · 2025Article
- Direct GPCR-EGFR interaction enables synergistic membrane-to-nucleus information transfer.Cellular and molecular life sciences : CMLS · 2024Article
- TrkB receptor interacts with mGluScience advances · 2024Article
- ACE2-EGFR-MAPK signaling contributes to SARS-CoV-2 infection.Life science alliance · 2023Article
- Gαq Is the Specific Mediator of PAR-1 Transactivation of Kinase Receptors in Vascular Smooth Muscle Cells.International journal of molecular sciences · 2022Article
- GPCR heteromers: An overview of their classification, function and physiological relevance.Frontiers in endocrinology · 2022Review
- Synergy of epidermal growth factor (EGFR) and angiotensin II (AT1R) receptor determines composition and temporal pattern of transcriptome variation.Cellular and molecular life sciences : CMLS · 2021Article
- Profiling novel pharmacology of receptor complexes using Receptor-HIT.Biochemical Society transactions · 2021Review
- Transactivation of G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs): Recent insights using luminescence and fluorescence technologies.Current opinion in endocrine and metabolic research · 2021Review
- Investigation of Receptor Heteromers Using NanoBRET Ligand Binding.International journal of molecular sciences · 2021Article
- Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism.Biochimica et biophysica acta. Molecular cell research · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 5 institutions in 4 countries.
Shannon L O'BrienReceptor Biology Group, The School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St Lucia 4072, Queensland, Australia.
Elizabeth K M JohnstoneMolecular Endocrinology and Pharmacology, Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands and Centre for Medical Research, The University of Western Australia, Crawley, Western Australia 6009, Australia.
Dominic DevostDepartment of Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.
Jacinta ConroyReceptor Biology Group, The School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St Lucia 4072, Queensland, Australia.
Melissa E ReicheltReceptor Biology Group, The School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St Lucia 4072, Queensland, Australia.
Brooke W PurdueReceptor Biology Group, The School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St Lucia 4072, Queensland, Australia.
Mohammed A AyoubMolecular Endocrinology and Pharmacology, Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands and Centre for Medical Research, The University of Western Australia, Crawley, Western Australia 6009, Australia.
Tatsuo KawaiCardiovascular Research Centre, Department of Physiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Asuka InoueGraduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi 980-8578, Japan.
Satoru EguchiCardiovascular Research Centre, Department of Physiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Terence E HébertDepartment of Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.
Kevin D G PflegerMolecular Endocrinology and Pharmacology, Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands and Centre for Medical Research, The University of Western Australia, Crawley, Western Australia 6009, Australia; Dimerix Limited, Nedlands, Western Australia 6009, Australia.
Walter G ThomasReceptor Biology Group, The School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St Lucia 4072, Queensland, Australia; Centre for Cardiac and Vasculature Biology, The University of Queensland, St Lucia 4072, Queensland, Australia. Electronic address: w.thomas@uq.edu.au.
The University of Queensland · AUThe University of Western Australia · AUMcGill University · CATemple University · USTohoku University · JP
Funding
EGF-ADAM17 axis in the pathophysiology of intracranial aneurysmR01NS109382 · NINDS · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI EGUCHI, SATORU, HASHIMOTO, TOMOKI · 2019 to 2023
$2.2MMechanism of Hypertensive Vascular Remodeling and End-Organ DamageR01HL133248 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI EGUCHI, SATORU · 2016 to 2019
$1.8MVascular signal as a therapeutic target for abdominal aortic aneurysmR01HL128324 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI EGUCHI, SATORU, RIZZO, VICTOR J. · 2015 to 2018
$1.6MNINDS NIH HHS R01 NS109382
Abstract
The type 1 angiotensin II (AngII) receptor (AT
Indexed as
AnimalsBioluminescence Resonance Energy Transfer TechniquesCHO CellsCricetulusErbB ReceptorsGTP-Binding Protein alpha Subunits, Gq-G11HEK293 CellsHumansMaleMiceNIH 3T3 CellsRatsRats, Sprague-DawleyReceptor, Angiotensin, Type 1Transcriptional ActivationEGFR protein, humanErbB ReceptorsGTP-Binding Protein alpha Subunits, Gq-G11Receptor, Angiotensin, Type 1Angiotensin IIBioluminescence resonance energy transferEGFR transactivationEpidermal growth factor receptorG protein-coupled receptorReceptor heteromerization
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.